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Background: Reloading with high-dose atorvastatin shortly before percutaneous coronary 
interventions (PCIs) has been proposed as a strategy to reduce periprocedural myonecrosis. There 
has been a concern that statins that are metabolized by cytochrome P450 3A4 may interfere with 
clopidogrel metabolism at high doses. The impact of simultaneous administration of high doses 
of atorvastatin and clopidogrel on the efficacy of platelet inhibition has not been established.
Methods: Subjects (n=60) were randomized to receive atorvastatin 80 mg together with 
clopidogrel 600 mg loading dose (n=28) versus clopidogrel 600 mg alone (n=32) at the time 
of PCI. Platelet aggregation was measured at baseline, 4 hours after clopidogrel loading dose, 
and 16–24 hours after clopidogrel loading dose by light transmittance aggregometry using 
adenosine diphosphate as agonist.
Results: Platelet aggregation was similar at baseline in both the atorvastatin and the control 
groups (adenosine diphosphate 10 µM: 57%±19% vs 61%±21%; P=0.52). There was no 
significant difference in platelet aggregation between the atorvastatin and the control groups 
at 4 hours (37%±18% vs 39%±21%; P=0.72) and 16–24 hours post-clopidogrel loading dose 
(35%±17% vs 37%±18%; P=0.75). No significant difference in incidence of periprocedural 
myonecrosis was observed between the atorvastatin and control groups (odds ratio: 1.02; 95% 
confidence interval 0.37–2.8).
Conclusion: High-dose atorvastatin given simultaneously with clopidogrel loading dose at 
the time of PCI does not significantly alter platelet inhibition by clopidogrel. Statin reloading 
with high doses of atorvastatin at the time of PCI appears to be safe without adverse effects on 
platelet inhibition by clopidogrel (ClinicalTrials.gov: NCT00979940).
Keywords: clopidogrel, atorvastatin, myocardial infarction, percutaneous coronary intervention, 
platelet aggregation
Introduction
High-dose statin therapy has been well established in the medical therapy of acute coro-
nary syndromes (ACS) and in secondary prevention of cardiovascular disease. Beyond the 
low-density lipoprotein lowering and high-density lipoprotein raising properties, pleiotro-
pic off-target effects of statins have been invoked in the dramatic reduction of thrombotic 
cardiovascular events. In the PROVE-IT TIMI 22 trial, intensive therapy with atorvastatin 
80 mg daily was superior to pravastatin 40 mg daily in reducing ischemic events after 
ACS with a 16% relative risk reduction for a composite end point of death, myocardial 
infarction, documented unstable angina requiring hospitalization, revascularization, 
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and stroke in the atorvastatin group.1 Similarly, others have 
investigated the beneficial properties of pretreatment with 
statins prior to elective percutaneous revascularization. 
A meta-analysis including nine trials documented an odds 
ratio of 0.45 for the occurrence of periprocedural myonecrosis 
in patients treated with statins prior to coronary intervention.2 
Whereas earlier studies included patients who were pretreated 
with statins for at least 2 days prior to percutaneous coro-
nary intervention (PCI), more recent trials have suggested 
that shorter pretreatment with statins may provide similar 
protection.3,4 In the NAPLES II study, atorvastatin 80 mg 
administered 24 hours prior to PCI significantly reduced the 
incidence of myocardial infarction in statin-naïve patients.4 
Similarly, in the ARMYDA-RECAPTURE study, reloading 
with atorvastatin 80 mg 12 hours prior to PCI and 40 mg 
immediately pre-PCI in patients on chronic statin therapy 
reduced the 30-day major adverse cardiovascular event rate 
from 9.4% to 3.7% (P=0.037).5
Clopidogrel is a prodrug that requires metabolism by the 
hepatic cytochrome P450 (CYP) system (2C19, 1A2, 2B6, 
3A4, 3A5, and 2C9 isoforms) to provide an active metabo-
lite.6 It has been shown that inhibition of CYP metabolic 
capacity such as in the case of CYP2C19 by omeprazole 
and other proton pump inhibitors can lead to inadequate 
clopidogrel metabolite formation and reduced platelet inhibi-
tion. High residual platelet reactivity during treatment with 
clopidogrel is associated with significantly increased risk for 
adverse ischemic events after PCI.7
Due to the common CYP3A4 pathway shared by many 
of the statins (simvastatin, atorvastatin, lovastatin) and 
clopidogrel, there has been a concern for clinically sig-
nificant interactions. A documented interaction between 
atorvastatin and clopidogrel was first described in 2003 by 
Lau et al,8 but other studies have not been able to confirm 
this effect using other platelet-testing modalities during 
maintenance therapy.9,10 Analysis of data from the CHA-
RISMA trial studying 10,078 patients with statin therapy at 
baseline randomized to dual therapy with clopidogrel and 
aspirin versus aspirin alone did not demonstrate an effect 
of CYP3A4-metabolized versus non-CYP3A4-metabolized 
statins on clinical end points.11 In clinical practice, admin-
istration of maintenance statin and antiplatelet agents is 
often separate, with the former generally being prescribed 
in the evening and the latter in the morning. However, as 
early upstream administration of high-dose atorvastatin 
is being increasingly adopted for patients admitted with 
ACS, concomitant administration with clopidogrel is more 
likely to occur. No study has so far investigated the effects 
of simultaneous administration of high-dose atorvastatin 
(80 mg) with high loading dose clopidogrel (600 mg) on 
early platelet inhibition post-PCI.
Methods
study design and patient population
The ESTATE study (effects of short term, high-dose aor-
vastatin therapy on periprocedural myonecrosis and platelet 
inhibition after PCI) is a randomized open-label pilot study 
to evaluate the effects of high-dose atorvastatin loading 
immediately before PCI on periprocedural myonecrosis and 
platelet inhibition. The study was approved by the Indiana 
University institutional review board. Written informed 
consent was obtained from all subjects. Subjects were eli-
gible to be enrolled in the study if they were found to have 
significant coronary artery disease (CAD) with angiographic 
stenosis of $70% in one or more coronary arteries and 
were undergoing PCI for stable CAD. Patients undergoing 
catheterization for ST-elevation myocardial infarction (MI), 
non-ST elevation MI, or high-risk unstable angina were 
not enrolled in the study. Exclusion criteria included age 
.85 years and ,21 years, recent myocardial infarction within 
the last month, cancer, renal failure with creatinine .3.0 mg/
dL, liver cirrhosis, lymphoproliferative disorder, pregnancy, 
thrombocytopenia ,150,000/mm3, coagulopathy (interna-
tional normalized ratio [INR] .1.5), abnormal liver function 
tests, illicit drug use, history of statin intolerance, history of 
rhabdomyolysis, and planned use of glycoprotein IIb/IIIa 
inhibitors during PCI. Given that only very few patients who 
were referred for cardiac catheterization were statin naïve, 
we allowed subjects who had received simvastatin (which 
was the primary statin prescribed in our institution) to be 
enrolled if last simvastatin dose was administered at least 
1 day prior. Subjects treated with atorvastatin, pravastatin, 
lovastatin, fluvastatin, or rosuvastatin were excluded from 
participation. All patients received aspirin 81–325 mg orally 
prior to diagnostic catheterization.
Patients were randomized 1:1 to receive either atorvas-
tatin 80 mg orally or no additional atorvastatin, along with 
standard clopidogrel 600 mg loading dose immediately prior 
to beginning of ad hoc PCI in the catheterization labora-
tory. Randomization occurred by opening of previously 
prepared sealed envelopes containing random allocation. 
The original sample size of the study (n=88) was calculated 
based on power 0.8 (two-sided alpha of 0.05) to detect the 
relative reduction in risk of periprocedural myonecrosis 
previously demonstrated in a study of moderate-dose ator-
vastatin pretreatment for several days before PCI.3 The study 
was stopped after 60 subjects due to slower than expected 
enrollment.
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Table 1 Baseline demographics and clinical variables
Variables Atorvastatin (n=28) Control (n=32) P-value
age (years) 62.6±10 61.4±8 0.6
Weight (kg) 97.9±32 103.7±48 0.58
Male sex (%) 22/28 (79%) 25/32 (78%) 0.97
race 0.33
caucasian (%) 22/28 (79%) 29/32 (91%)
african american (%) 5/28 (18%) 3/32 (9.4%)
asian (%) 1/28 (4%) 0/32 (0%)
Prior caD (%) 17/28 (61%) 22/32 (69%) 0.52
congestive heart failure (%) 4/28 (14%) 5/32 (16%) 0.89
Diabetes mellitus (%) 13/28 (46%) 14/32 (44%) 0.84
hypertension (%) 27/28 (96%) 30/31 (97%) 0.92
hyperlipidemia (%) 25/28 (89%) 29/32 (91%) 0.86
current smoking (%) 11/28 (39%) 10/32 (31%) 0.66
Baseline clopidogrel use (%) 7/28 (25%) 6/32 (19%) 0.56
Daily aspirin dose 0.6
81 mg 11/28 (39%) 12/32 (38%)
162 mg 0/28 (0%) 1/32 (3%)
325 mg 17/28 (61%) 9/32 (59%)
Prior treatment with simvastatin (%) 21/28 (75%) 22/32 (69%) 0.59
Proton pump inhibitor (%) 10/28 (36%) 13/32 (41%) 0.63
ace inhibitors (%) 17/28 (61%) 20/32 (63%) 0.76
Beta blockers (%) 26/28 (93%) 26/32 (81%) 0.29
calcium channel blockers (%) 6/28 (21%) 5/32 (16%) 0.6
coronary artery intervention
left anterior descending artery 9/28 (32%) 11/32 (34%) 0.86
Circumflex artery 8/28 (29%) 11/32 (34%) 0.63
right coronary artery 14/28 (50%) 13/32 (41%) 0.47
number of stents implanted 1.48±1.2 1.58±0.8 0.71
Notes: Data presented as mean ± standard deviation unless otherwise stated. comparison of variables with student’s t-test for continuous variables and χ2 for categorical 
variables.
Abbreviations: caD, coronary artery disease; ace, angiotensin-converting enzyme.
Blood samples
Blood samples were taken from arterial sheaths in the cathe-
terization laboratory before administration of clopidogrel 
and atorvastatin. Follow-up blood samples were obtained by 
venipuncture 4 hours and 16–24 hours after loading dose of 
clopidogrel. All blood samples were directly transferred into 
vacutainer tubes containing Na citrate 3.2% and analyzed 
within 2 hours. Light transmittance aggregometry was performed 
with a Chronolog 700 aggregometer in platelet-rich plasma using 
platelet poor plasma as reference as previously described.12,13 
Adenosine diphosphate (ADP) at 5 µM, 10 µM, and 20 µM was 
used as agonist. Platelet inhibition was defined as % change in 
platelet aggregation from baseline in subjects not on baseline 
clopidogrel. Cardiac troponin I and creatinine kinase-MB 
(CK-MB) were measured 8 hours and 16 hours after PCI.
end points
Periprocedural myonecrosis was defined as a rise in cardiac tro-
ponin I above the upper limit of normal (ULN) for the assay at 
any time point after PCI. Periprocedural myocardial infarction 
was defined as postprocedural rise in CK-MB .3× ULN.14
statistics
Statistical analysis was performed using SPSS 22.0 (IBM 
Corporation, Armonk, NY, USA). Statistical significance was 
defined as P,0.05. Two-sided tests were conducted, and the 
values are represented as mean ± standard deviation except 
as otherwise stated. Categorical variables were compared 
using the χ2-test. Normal distribution of continuous data was 
assessed by the Kolmogorov–Smirnov test. Unpaired two-
sided Student’s t-test was used to compare normally distrib-
uted continuous data between the two groups. Multivariable 
linear regression analysis was performed using on-treatment 
platelet aggregation as dependent variable to evaluate the 
effects of assigned treatment arm with forward stepwise 
adjustment for baseline clinical variables, as well as adjust-
ment for prior treatment with simvastatin and clopidogrel.
Results
Sixty patients who were undergoing elective PCI were ran-
domized to receive either atorvastatin 80 mg together with 
clopidogrel 600 mg loading dose (n=28) or clopidogrel 
600 mg alone (n=32).
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Figure 1 Platelet aggregation.
Note: Maximal platelet aggregation measured at baseline (A), 4 hours (B), and 24 hours (C) after clopidogrel loading dose administration.
Abbreviation: aDP, adenosine diphosphate.
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Figure 2 Platelet inhibition 4 hours (A) and 24 hours (B) after clopidogrel loading dose. Periprocedural myonecrosis after Pci (C).
Abbreviations: aDP, adenosine diphosphate; cK-MB, creatinine kinase-MB; Pci, percutaneous coronary intervention.
One patient in the control (no atorvastatin) group received 
abciximab during the procedure at the discretion of the 
operator and was excluded from the analysis in the platelet 
substudy. Clinical variables of the subjects enrolled in the 
study are delineated in Table 1. There were no significant dif-
ferences in the prevalence of clinical variables among groups. 
An average of 1.53 stents were implanted during the PCI, with 
91% being drug-eluting stents. The target vessel was the left 
anterior descending artery in 33%, the circumflex artery in 
32%, and the right coronary artery in 45% of cases.
At baseline prior to clopidogrel and atorvastatin adminis-
tration, there was no significant difference in baseline platelet 
aggregation induced by ADP (Figure 1A). Platelet aggrega-
tion decreased at 4 hours after clopidogrel administration 
in both the atorvastatin and the control groups, with only 
minimal additional decrease in maximal platelet aggregation 
for all agonists studied at 16–24 hours (Figures 1B and C). 
There was a nonsignificant trend toward lower on-treatment 
maximal platelet aggregation in the atorvastatin group as 
compared to the control group at both time points. Similarly, 
there was no significant difference in platelet inhibition 
between the atorvastatin and control groups (Figures 2A and 
B). Multivariable linear regression analysis demonstrated no 
significant association between atorvastatin treatment arm 
and final on-treatment platelet aggregation after adjustment 
for clinical variables and pretreatment with clopidogrel or 
simvastatin (Table 2).
As previously reported by other investigators, a large 
number of subjects with uncomplicated PCI demonstrated 
periprocedural myonecrosis, as defined by elevation in 
cardiac troponin I above the ULN (Figure 2C). A smaller 
fraction of subjects demonstrated a rise in CK-MB above the 
ULN (Figure 2C). For both measures, no difference in inci-
dence of periprocedural myonecrosis was observed between 
atorvastatin and control groups (troponin .1× ULN: odds 
ratio: 1.02; 95% confidence interval [CI] 0.37–2.8; P=0.97; 
CK-MB .1× ULN: odds ratio: 0.84; 95% CI 0.17–4.1; 
P=0.83). Two subjects in the atorvastatin group and one 
subject in the control group had a periprocedural myocardial 
infarction as defined by CK-MB rise above 3× ULN (odds 
ratio: 2.4; 95% CI 0.2–28; P=0.5).
Discussion
The results of our study suggest that simultaneous admini-
stration of high-dose atorvastatin 80 mg and clopidogrel 
600 mg loading doses does not significantly increase the risk 
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Table 2 Multivariable analysis of atorvastatin treatment with 
forward stepwise adjustment for baseline clinical variables and 
baseline clopidogrel and simvastatin treatment
Dependent variable:  
maximal platelet  
aggregation at 16–24 hours
B-value 95% Confidence  
interval
P-value
aDP 5 µM -2.6 -11.2 to 5.9 0.54
aDP 10 µM -0.7 -10.7 to 9.3 0.89
aDP 20 µM -4.0 -13 to 5.1 0.39
Abbreviation: aDP, adenosine diphosphate.
of high posttreatment platelet reactivity. While our study 
was not powered to demonstrate effectiveness in reducing 
the risk of periprocedural myocardial necrosis, given early 
termination of the study prior to targeted enrollment, and 
its pilot design, there was no difference in rates of peripro-
cedural myonecrosis between subjects with and without 
concomitant high-dose atorvastatin administration. Previous 
studies by other investigators have suggested that high-dose 
atorvastatin given within a short time interval of 12 hours 
before PCI in patients with ACS may significantly reduce 
the risk of major cardiac events. In addition, updated guide-
lines recommend atorvastatin 40–80 mg/d or rosuvastatin 
20–40 mg/d for secondary prevention of CAD.15 Thus, high 
doses of atorvastatin are increasingly being coprescribed 
in patients undergoing ad hoc PCI who may be started on 
clopidogrel concomitantly during an admission for an ACS. 
Many studies have evaluated the pharmacodynamic inter-
actions of CYP3A4-metabolized statins and clopidogrel, 
with the majority evaluating the effects of chronic statin 
exposure on platelet reactivity.8–11,16–22 The timing of peak 
hepatic plasma exposure to the parent drugs may affect the 
extent of the pharmacodynamic interaction. The majority 
of studies examining statin–clopidogrel interaction have 
used traditional timing of dose administration, with statins 
being prescribed in the evening and antiplatelet agents in 
the morning. This may significantly influence the degree of 
interaction given that atorvastatin has a terminal half-life 
of ∼10 hours.23 The majority of studies have demonstrated 
no consistent effect of atorvastatin treatment on clopidogrel 
response or clinical event rates, with few exceptions. 
Leoncini et al24 demonstrated improved platelet inhibition 
among patients randomized to high-dose atorvastatin who 
were previously found to have high platelet reactivity on 
clopidogrel. Some studies have suggested a modest pleio-
tropic anti-aggregatory effect of low-dose atorvastatin 
with reduction of ADP platelet reactivity after treatment 
for several months as well as improvement in prevalence 
of aspirin resistance, which could in part counterbalance a 
reduction in clopidogrel platelet inhibition.25,26 In contrast, 
Park et al18 showed that changing atorvastatin to a 
non-3A4-metabolized statin significantly improved platelet 
inhibition among nonresponders to clopidogrel with high 
posttreatment platelet reactivity. Pelliccia et al27 recently 
reported that treatment with low-dose atorvastatin was 
associated with a small but significant increase in platelet 
reactivity among patients treated with clopidogrel, but this 
effect was only observed in subjects with high baseline 
on-treatment platelet reactivity by Verify Now assay. These 
conflicting results suggest that among certain individu-
als, in particular subjects who have high residual platelet 
reactivity during treatment with clopidogrel, concomitant 
treatment with high-dose atorvastatin could contribute to 
differences in pharmacodynamic response to clopidogrel. 
However, the results of this study suggest that simultaneous 
administration of high-dose atorvastatin and clopidogrel 
loading dose does not significantly impair early platelet 
inhibition after PCI, which is supported by lack of dif-
ferences in outcomes among patients with statins in large 
clinical trials of clopidogrel.11,28,29
Limitations of this study include the open-label study 
design and that not all patients were naïve to statins and 
clopidogrel at the time of enrollment. Also, no other platelet 
agonists were studied other than ADP. Additional limitations 
are the relatively small sample size and the premature termi-
nation of the study after slow enrollment, leading to decrease 
in power to detect significant differences in incidence of 
periprocedural myonecrosis.
Conclusion
The results of our study indicate that simultaneous adminis-
tration of high-dose atorvastatin and clopidogrel prior to PCI 
appears to be safe and does not significantly alter platelet 
inhibition by clopidogrel.
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